SparingVision’s €44.5 Million Series A2 Fundraising


Dechert advised the investors in the transaction.

SparingVision completed its €44.5 million Series A2 fundraising, with UPMC Enterprises, 4Bio Capital and Ysios Capital acting as investors.

SparingVision is a biotechnology company specialized in the research and development of an innovative therapeutic approach for the treatment of inherited retinal degenerative diseases such as retinitis pigmentosa.

Dechert advised the investors on legal aspects with, in corporate, partner Anne-Charlotte Rivière (Picture), with Aude Steinberg and Johann Gandilhon, associates, in intellectual property, Marie Fillon, national partner with Louis de Chezelles, associate, in labor, Thibault Meiers, national partner with Maëlle Chausse, associate.

Involved fees earner: Maëlle Chausse – Dechert; Louis de Chezelles – Dechert; Marie Fillon – Dechert; Johann Gandilhon – Dechert; Thibault Meiers – Dechert; Anne-Charlotte Rivière – Dechert; Aude Steinberg – Dechert;

Law Firms: Dechert;

Clients: 4Bio Capital; UPMC Enterprises; Ysios Capital;